Aspects of health and environmental services using TES therapy

Abstract

Considering the prevalence of coronary heart disease and myocardial infarction, the problem of improving the pharmacotherapy of coronary heart disease continues to be one of the most urgent problems in modern pharmacology. In recent years, the point of view has become generally accepted that the most real factor in both the initiation and progression of atherosclerosis and the development of its acute clinical manifestations is inflammation, and the destabilization of an atherosclerotic plaque is determined by the high activity of a chronic inflammatory process in it. The most promising theory of atherogenesis is that the accumulation and increased content of cytokines in the peripheral blood against the background of changes in the initial level of cholesterol (CS) may be the primary trigger of the atherosclerotic process.